NIBRT, Valitacell Aim to Validate New Analytical Technology
The partnership, co-funded by Enterprise Ireland, will develop technologies for monitoring the quality of biopharma processes.
In a partnership with biotechnology firm Valitacell, formed in early November 2018, the National Institute of Bioprocessing Research and Training (NIBRT) aims to validate a new analytical technology developed by Valitacell known as ChemStress, which can accelerate the development and manufacture of biopharmaceutical therapies.
The collaboration, which also involves a number of large global biopharmaceutical companies, will demonstrate how Valitacell’s ChemStress can be used for quality control in cell culture media analysis. Jonathan Bones, principal investigator, NIBRT Characterization and Comparability Laboratory, will lead the project, along with Valitacell’s product manager, Karen Coss.
Valitacell technology enables companies to ensure that the media added to cells meets the quality standards that the companies have set for themselves, through smart analytics.
“We are delighted to be working with Prof. Jonathan Bones and his team. Having access to outstanding researchers and facilities at NIBRT will enable us to accelerate the development of our technology and help in our goal of bringing life-saving medicines to patients more quickly and at lower cost,” said Terry McWade, Valitacell’s CEO, in a company press release.
“NIBRT are delighted to engage with Valitacell on this exciting project. Valitacell are developing innovative technologies for monitoring the quality and behavior of complex biomanufacturing processes. Our analytical platforms strongly complement Valitacell’s ChemStress technology, and we share a common vision to ensure more efficient manufacturing of these key biological medicines,” said Bones in the press release.
The project is an Innovation Partnership co-funded by Enterprise Ireland, the European Regional Development Fund (ERDF) and the European Union. The EUR 206,283 (US$ 233,659) award will run over 18 months. The project began in November 2018.
Source: NIBRT
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
